BACKGROUND: Radiofrequency ablation (RFA) is a radical treatment for both primary and recurrent @entity157 ( @entity157 ) with an optimistic outcome which is comparable with surgery. For localized recurrence of @entity157 after liver transplantation (LTx), surgical resection is considered the most favorable treatment. When surgical resection is contraindicated or technically infeasible, whether RFA is as efficient after transplantation as in nontransplant settings remains unclear. MATERIALS AND METHODS: A cohort study was undertaken in a population of @entity1 that had a recurrence of @entity157 after LTx to evaluate the outcomes of different modalities (surgery, RFA, and conservative therapy) on long-term survival. RESULTS: Seventy-eight of the 486 @entity157 @entity1 who received LTx had a recurrence (16%). Fifteen @entity1 underwent surgical resection, and 11 @entity1 were treated with RFA. The remaining 52 @entity1 received conservative therapy (17 @entity1 with @entity3446 plus @entity2857 regimen; the others were treated with conventional supportive therapy). The 1-, 3-, and 5-y overall survival rates were 92%, 51%, and 35% for the @entity1 treated with surgery and 87%, 51%, and 28% for the @entity1 that received RFA. The corresponding 1-, 3-, and 5-y rerecurrence-free survival rates were 83%, 16%, and 16% for the @entity1 treated with surgery and 76%, 22%, and 0% for the @entity1 that received RFA, respectively. There was no significant difference in overall survival or rerecurrence-free survival between the surgical resection group and the RFA group (P  =  0.879, P  =  0.745). CONCLUSIONS: For @entity157 recurrence after LTx, RFA is preferable when surgical resection is contraindicated or technically infeasible and provides comparable long-term survival compared with surgery.

Is radiofrequency ablation applicable for recurrent XXXX after liver transplantation?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'small hepatocellular carcinoma'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
